Guardant Health, Inc. (NASDAQ:GH) Shares Acquired by Nikko Asset Management Americas Inc.

Nikko Asset Management Americas Inc. increased its position in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 15.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,464,213 shares of the company's stock after acquiring an additional 197,729 shares during the quarter. Nikko Asset Management Americas Inc. owned approximately 1.19% of Guardant Health worth $44,732,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of GH. Arizona State Retirement System lifted its stake in shares of Guardant Health by 1.1% in the 4th quarter. Arizona State Retirement System now owns 35,639 shares of the company's stock valued at $1,089,000 after purchasing an additional 403 shares during the last quarter. Jones Financial Companies Lllp raised its holdings in Guardant Health by 43.5% in the 4th quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock valued at $82,000 after buying an additional 817 shares during the period. Fiduciary Alliance LLC lifted its position in Guardant Health by 7.6% in the fourth quarter. Fiduciary Alliance LLC now owns 11,879 shares of the company's stock valued at $363,000 after buying an additional 836 shares during the last quarter. R Squared Ltd purchased a new position in Guardant Health during the fourth quarter worth about $26,000. Finally, Van ECK Associates Corp increased its position in shares of Guardant Health by 47.4% during the fourth quarter. Van ECK Associates Corp now owns 2,887 shares of the company's stock valued at $88,000 after acquiring an additional 929 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

GH has been the subject of a number of research analyst reports. Canaccord Genuity Group increased their price objective on shares of Guardant Health from $42.00 to $60.00 and gave the stock a "buy" rating in a research report on Monday, February 24th. JPMorgan Chase & Co. raised their price target on Guardant Health from $50.00 to $55.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. Guggenheim reiterated a "buy" rating and issued a $56.00 price objective on shares of Guardant Health in a report on Monday, February 24th. Piper Sandler increased their target price on Guardant Health from $34.00 to $50.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Finally, Scotiabank lifted their target price on Guardant Health from $47.00 to $52.00 and gave the company a "sector outperform" rating in a research report on Monday, February 24th. Twenty equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $48.40.

Guardant Health Stock Up 3.1 %

GH traded up $1.38 on Friday, reaching $46.10. The company's stock had a trading volume of 2,065,078 shares, compared to its average volume of 2,142,637. The company has a market capitalization of $5.69 billion, a price-to-earnings ratio of -12.95 and a beta of 1.50. Guardant Health, Inc. has a fifty-two week low of $15.81 and a fifty-two week high of $50.89. The stock has a 50 day moving average of $43.66 and a two-hundred day moving average of $33.36.

Guardant Health (NASDAQ:GH - Get Free Report) last posted its earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The company had revenue of $201.81 million during the quarter, compared to analysts' expectations of $192.50 million. As a group, analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.